26 research outputs found

    Structural dynamics of first-order phase transition in giant magnetocaloric La(Fe,Si)13: The free energy landscape

    Get PDF
    Maximizing the performance of magnetic refrigerators and thermomagnetic energy harvesters is imperative for their successful implementation and can be done by maximizing their operation frequency. One of the features delimiting the frequency and efficiency of such devices is the phase transition kinetics of their magnetocaloric/thermomagnetic active material. While previous studies have described the magnetic component governing the kinetics of the magnetovolume phase transition in La(Fe,Si)13 giant magnetocaloric materials, a comprehensive description of its structural component has yet to be explored. In this study, in situ synchrotron X-ray diffraction is employed to describe the structural changes upon magnetic field application/removal. Long magnetic field dependent relaxation times up to a few hundred seconds are observed after the driving field is paused. The phase transition is found to be highly asymmetric upon magnetic field cycling due to the different Gibbs energy landscapes and the absence of an energy barrier upon field removal. An exponential relationship is found between the energy barriers and the relaxation times, suggesting the process is governed by a non-thermal activation over an energy barrier process. Such fundamental knowledge on first-order phase transition kinetics suggests pathways for materials optimization and smarter design of magnetic field cycling in real-life devices

    Fine control of Curie temperature of magnetocaloric alloys La(Fe,Co,Si)13 using electrolytic hydriding

    Get PDF
    This work demonstrates precision control of hydrogen content in La(Fe,Co,Si)13Hδ for the development of environmentally friendly magnetocaloric-based cooling technologies, using an electrolytic hydriding technique. We show the Curie temperature, a critical parameter which directly governs the temperature window of effective cooling, can be varied easily and reproducibly in 1 K steps within the range 274 K to 402 K. Importantly, both partially (up to 10%) and fully hydrided compositions retain favorable entropy change values comparable to that of the base composition. Crucially, we show in these second-order phase transition compounds, partial hydriding is stable and not susceptible against phase separation

    Polymorphism in a T-cell receptor variable gene is associated with susceptibility to a juvenile rheumatoid arthritis subset

    Full text link
    This report demonstrates a T-cell receptor (Tcr) restriction fragment length polymorphism, defined by a Tcrb-V6.1 gene probe and Bgl II restriction enzyme, to be absolutely correlated with allelic variation in the coding sequence of a Tcrb-V6.1 gene. A pair of non-conservative amino acid substitutions distinguish the Tcrb-V6.1 allelic variants. An association of this Tcrb-V6.1 gene allelic variant with one form of juvenile rheumatoid arthritis (JRA) was established in a cohort of 126 patients. The association was observed in patients possessing the HLA-DQA1*0101 gene. Among HLA-DQA*0101 individuals, 19 of 26 patients (73.1%) carried one particular Tcrb-V6.1 gene allele as opposed to 11 of 33 controls (33%; p<0.005). Haplotypes carrying this HLA gene have previously been shown to confer increased risk for progression of arthritis in JRA. This demonstration of a disease-associated Tcrb-V gene allelic variant has not, to our knowledge, been previously reported and supports the contribution of polymorphism in the Tcr variable region genomic repertoire to human autoimmune disease.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/46750/1/251_2004_Article_BF00166831.pd

    Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome
    corecore